Mucopolysaccharidosis I clinical trials
The registry lists 74 studies for Mucopolysaccharidosis I across more than 10 countries. 7 are recruiting or about to start. 54 of them are mainly about Mucopolysaccharidosis I (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-04.
Get an email when these change. Save the Mucopolysaccharidosis I studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your saved searches, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your saved searches. Stop any time.
Who runs them
Genzyme, a Sanofi Company (10) · Masonic Cancer Center, University of Minnesota (9) · ArmaGen, Inc (4) · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center (3) · University of Minnesota (3) · Patricia I. Dickson, M.D. (3) · Paul Szabolcs (2) · JCR Pharmaceuticals Co., Ltd. (2)
What is being tested here
Drugs under test in Mucopolysaccharidosis I studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
| Drug | Open | Phase 3 | All |
|---|---|---|---|
| Alemtuzumab | 1 | 0 | 3 |
| Hydroxyurea | 1 | 0 | 1 |
| Fludarabine | 1 | 0 | 1 |
| Melphalan | 1 | 0 | 1 |
| Thiotepa | 1 | 0 | 1 |
| Laronidase | 0 | 3 | 16 |
| Valanafusp alpha | 0 | 0 | 4 |
| Cyclophosphamide | 0 | 0 | 3 |
| Busulfan | 0 | 0 | 3 |
| Adalimumab | 0 | 0 | 2 |
Drug classes tested here Alkylating agents 1 open
Coming up
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
All 5
- Nov 2026Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT · Paul Szabolcs
- Nov 2026Early Check: Expanded Screening in Newborns · RTI International
- Dec 2026MPS (RaDiCo Cohort) (RaDiCo-MPS) · Institut National de la Santé Et de la Recherche Médicale, France
- Jan 2027Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VI · Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Sep 2027Long Term Follow-Up for RGX-111 · REGENXBIO Inc.
Who these studies take
Of the 6 Mucopolysaccharidosis I studies recruiting now, 3 (50%) set no upper age limit and 3 (50%) stop at 75 or younger. 5 (83%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 0 (0%) take healthy volunteers.
| Age | Women | Men |
|---|---|---|
| 10 | 5 (83%) | 5 (83%) |
| 18 | 6 (100%) | 6 (100%) |
| 30 | 6 (100%) | 6 (100%) |
| 40 | 6 (100%) | 6 (100%) |
| 50 | 6 (100%) | 6 (100%) |
| 65 | 3 (50%) | 3 (50%) |
| 75 | 3 (50%) | 3 (50%) |
| 85 | 3 (50%) | 3 (50%) |
Across all 74 studies, recruiting or not: 47% stop at 75 or younger and 47% at 65; 92% take children; 1% are for women only and 1% for men only; 4% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
Studies
Recruiting first, then most recently updated. Showing 50 of 74. Browse all 74 → or search them.
- ISP-001: Sleeping Beauty Transposon-Engineered B Cells for MPS IRecruitingNCT05682144Phase 11 country
- Long Term Follow-Up for RGX-111Enrolling by invitationNCT061034872 countries
- Registry of Patients Diagnosed With Lysosomal Storage DiseasesRecruitingNCT056199001 country
- MPS (RaDiCo Cohort) (RaDiCo-MPS)RecruitingNCT060366931 country
- Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RICRecruitingNCT045283551 country
- Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCTRecruitingNCT01962415Phase 21 country
- A Clinical Study Evaluating the Safety, Tolerability, and Initial Efficacy of JWK008 in Patients With Mucopolysaccharidosis Type IRecruitingNCT06519552Phase 11 country
- Evaluation of Intravenous Laronidase Pharmacokinetics Before and After Hematopoietic Cell Transplantation in Patients With Mucopolysaccharidosis Type IH.Active, not recruitingNCT056345121 country
- MT2013-31: Allo HCT for Metabolic Disorders and Severe OsteopetrosisActive, not recruitingNCT02171104Phase 21 country
- Long Term Follow-up (LTFU) of Subjects Who Received SB-318, SB-913, or SB-FIXTerminatedNCT046288711 country
- Gene Therapy With Modified Autologous Hematopoietic Stem Cells for the Treatment of Patients With Mucopolysaccharidosis Type I, Hurler VariantActive, not recruitingNCT03488394Phase 1/21 country
- Early Check: Expanded Screening in NewbornsActive, not recruitingNCT036552231 country
- RGX-111 Gene Therapy in Patients With MPS ISuspendedNCT03580083Phase 1/22 countries
- Mucopolysaccharidosis I (MPS I) RegistryCompletedNCT0014479437 countries
- Study to Evaluate the Safety and Efficacy of Adalimumab in MPS I, II, and VIActive, not recruitingNCT03153319Phase 1/21 country
- A Study to Investigate the Efficacy and Safety of OTL-203 in Subjects With MPS-IH Compared With Standard of Care With Allogeneic HSCTActive, not recruitingNCT06149403Phase 34 countries
- China Post-marketing Surveillance (PMS) Study of Aldurazyme®CompletedNCT05134571Phase 41 country
- An Extension Study of JR-171-101 Study in Patients With Mucopolysaccharidosis Type I (MPS I)CompletedNCT04453085Phase 1/23 countries
- Baby Detect : Genomic Newborn ScreeningCompletedNCT056874741 country
- A Study of JR-171 in Patients With Mucopolysaccharidosis ICompletedNCT04227600Phase 1/23 countries
- Long Term Follow Up Of Patients Who Have Received Gene Therapy Or Gene Marked ProductsCompletedNCT006952791 country
- Efficacy and Safety of YW17 (Laronidase-CinnaGen) Compared to Aldurazyme® in MPS I PatientsCompletedNCT06406153Phase 31 country
- A Study of the Effect of Aldurazyme® (Laronidase) Treatment on Lactation in Female Patients With Mucopolysaccharidosis I (MPS I) and Their Breastfed InfantsTerminatedNCT00418821Phase 41 country
- A Study to Assess the Safety of Myozyme® and of Aldurazyme® in Male and Female Participants of Any Age Group With Pompe Disease or With Mucopolysaccharidosis Type I (MPS I) in a Home-care SettingCompletedNCT050737831 country
- Extension Study of Intrathecal Enzyme Replacement for Cognitive Decline in MPS ITerminatedNCT02232477Not applicable1 country
- Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell TransplantationCompletedNCT03513328Phase 1/21 country
- Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic DisordersTerminatedNCT01372228Phase 1/21 country
- Safety and Efficacy of Encapsulated Allogeneic MPS-1 TherapyWithdrawnNCT05665036Phase 1/22 countries
- Extension Study Evaluating Long Term Safety and Activity of AGT-181 in Children With MPS ICompletedNCT03071341Phase 1/21 country
- Safety and Dose Ranging Study of Human Insulin Receptor MAb-IDUA Fusion Protein in Adults and Children With MPS ICompletedNCT03053089Phase 1/21 country
- Safety and Dose Ranging Study of Insulin Receptor MAb-IDUA Fusion Protein in Patients With MPS ICompletedNCT02371226Phase 11 country
- Biomarker for Hurler Disease (BioHurler)WithdrawnNCT022987124 countries
- Biomarker for Gangliosidosis: BioGM1/BioGM2 (BioGM1/GM2)WithdrawnNCT022986474 countries
- Ascending Dose Study of Genome Editing by the Zinc Finger Nuclease (ZFN) Therapeutic SB-318 in Subjects With MPS ITerminatedNCT02702115Phase 1/21 country
- Human Placental-Derived Stem Cell TransplantationCompletedNCT01586455Phase 11 country
- MGTA-456 in Patients With Inherited Metabolic Disorders Undergoing Hematopoietic Stem Cell Transplantation (HSCT)CompletedNCT03406962Phase 21 country
- S 81694 Plus Paclitaxel in Metastatic Breast CancerCompletedNCT03411161Phase 1/24 countries
- Mucopolysaccharidosis (MPS) I, II, and VI Screening in a High-Risk Population With Previous Surgical Repair or Presence of Inguinal and/or Umbilical Hernia in Combination With Pediatric ENT Surgery (The HATT Project)TerminatedNCT020950157 countries
- A Follow-up Study in Patients With Inherited Metabolic Disorders (IMD) Who Underwent Hematopoietic Stem Cell Transplantation (HSCT) With MGTA-456TerminatedNCT040088491 country
- BPX-501 T Cells Infused Post Stem Cell Transplant in Pediatrics With Non-Malignant Disorders Ineligible for BPU004 StudyNo longer availableNCT036398441 country
- Administration of IV Laronidase Post Bone Marrow Transplant in HurlerCompletedNCT01173016Phase 11 country
- Bone Marrow Transplant With Abatacept for Non-Malignant DiseasesCompletedNCT01917708Phase 11 country
- Neurobehavioral Phenotypes in MPS IIICompletedNCT018739111 country
- MRS to Determine Neuroinflammation and Oxidative Stress in MPS ICompletedNCT035767291 country
- Lysosomal Storage Disease: Health, Development, and Functional Outcome Surveillance in Preschool ChildrenCompletedNCT019380141 country
- Longitudinal Studies of Brain Structure and Function in MPS DisordersCompletedNCT018703752 countries
- Stem Cell Transplant w/Laronidase for HurlerCompletedNCT00176891Phase 21 country
- Effects of Growth Hormone in Chronically Ill ChildrenWithdrawnNCT00286689Not applicable1 country
- Intrathecal Enzyme Replacement for Hurler SyndromeCompletedNCT00638547Phase 11 country
- Safety and Exploratory Efficacy of HSC835 in Patients With Inherited Metabolic Disorders (IMD)WithdrawnNCT02715505Phase 1/2